Search details
1.
Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors.
J Immunol
; 211(2): 219-228, 2023 07 15.
Article
in English
| MEDLINE | ID: mdl-37204246
2.
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Lancet Oncol
; 25(4): 474-487, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38547892
3.
Body mass index and patient-reported function, quality of life and treatment toxicity in women receiving adjuvant chemotherapy for breast cancer.
Support Care Cancer
; 31(3): 196, 2023 Mar 02.
Article
in English
| MEDLINE | ID: mdl-36859693
4.
Patient-reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer.
Cancer
; 127(6): 957-967, 2021 03 15.
Article
in English
| MEDLINE | ID: mdl-33216355
5.
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
Breast Cancer Res Treat
; 181(3): 623-633, 2020 Jun.
Article
in English
| MEDLINE | ID: mdl-32378051
6.
Nanoparticle-Delivered Chemotherapy: Old Drugs in New Packages.
Oncology (Williston Park)
; 31(3): 198-208, 2017 Mar 15.
Article
in English
| MEDLINE | ID: mdl-28299757
7.
A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience.
Oncologist
; 21(1): 16-20, 2016 Jan.
Article
in English
| MEDLINE | ID: mdl-26659221
8.
Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study.
Lancet Oncol
; 16(4): 395-405, 2015 Apr.
Article
in English
| MEDLINE | ID: mdl-25728526
9.
Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.
Breast Cancer Res Treat
; 145(1): 245-54, 2014 May.
Article
in English
| MEDLINE | ID: mdl-24706167
10.
Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial.
JAMA Oncol
; 10(2): 193-201, 2024 Feb 01.
Article
in English
| MEDLINE | ID: mdl-38095878
11.
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.
Clin Cancer Res
; 2024 May 21.
Article
in English
| MEDLINE | ID: mdl-38771739
12.
A phase II single-arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effects.
Cancer Med
; 12(7): 8172-8183, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36645168
13.
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit.
Commun Med (Lond)
; 3(1): 14, 2023 Feb 07.
Article
in English
| MEDLINE | ID: mdl-36750617
14.
Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer.
Oncologist
; 17(12): 1496-503, 2012.
Article
in English
| MEDLINE | ID: mdl-23006498
15.
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.
Breast Cancer Res Treat
; 134(1): 401-10, 2012 Jul.
Article
in English
| MEDLINE | ID: mdl-22527101
16.
Phase II open-label study of sunitinib in patients with advanced breast cancer.
Breast Cancer Res Treat
; 136(3): 759-67, 2012 Dec.
Article
in English
| MEDLINE | ID: mdl-23073758
17.
Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.
Br J Clin Pharmacol
; 74(1): 197-200, 2012 Jul.
Article
in English
| MEDLINE | ID: mdl-22680343
18.
Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer.
J Immunother Cancer
; 10(2)2022 02.
Article
in English
| MEDLINE | ID: mdl-35121644
19.
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013.
NPJ Breast Cancer
; 8(1): 134, 2022 Dec 30.
Article
in English
| MEDLINE | ID: mdl-36585404
20.
Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.
Ann Surg Oncol
; 18(10): 2851-7, 2011 Oct.
Article
in English
| MEDLINE | ID: mdl-21442348